Eisai Company, Limited

Toshio Seto

Kentaro Yoshimatsu

Toshio Osawa

Isao Tanaka

Yukio Ohya

Yoshikazu Hasegawa

Yasushi Shikata

Yoshiharu Mizui

Suguru Suzuki

Naoko Nagaoka

Shinji Yoshitake

Hiroyuki Kato

Noboru Suzuki

A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template. The invention also relates to a method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.

Human antithrombin III mutants

A recombinant natural killer cell activating factor is disclosed, preferably having a peptide of the following amino acid sequence in its molecule. The invention provides a cDNA coding for a recombinant natural killer cell activating factor, a expression plasmid involving the cDNA, a host transformed with the plasmid, an antitumor agent containing the recombinant natural killer cell activating factor and a pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent and a pharmacologically acceptable carrier.

Recombinant natural killer cell activator

Growing community of inventors

Ibaraki, Japan

Toshio Seto